Literature DB >> 28462682

Focal Electroencephalographic Changes Index Post-Traumatic Confusion and Outcome.

Sudhin A Shah1, Maliheh Mohamadpour2, Gulce Askin3, Risa Nakase-Richardson4, Dobrivoje S Stokic5, Mark Sherer6, Stuart A Yablon5, Nicholas D Schiff7.   

Abstract

While the duration and severity of post-traumatic confusional state (PTCS) after traumatic brain injury have well-established implications for long-term outcomes, little is known about the underlying pathophysiology and their role in functional outcomes. Here, we analyzed the delta-to-alpha frequency band power ratios (DAR) from localized scalp areas derived from standard resting electroencephalographic (EEG) data recorded during eyes closed state in 49 patients diagnosed with PTCS. Higher global, occipital, parietal, and temporal DARs were significantly associated with the severity of PTCS, as assessed by the Confusion Assessment Protocol (CAP) observed on the same day, after controlling for injury severity. Also, occipital DARs were positively associated with both the CAP disorientation score 2, and the CAP symptom fluctuation score 4, after controlling for injury severity (n = 35). Posterior DARs were significantly associated with Functional Independence Measure-cognitive subscale average score at 1 (n = 45), 2 (n = 42), and 5 (n = 34) year(s) post-injury. The associations at 1 (temporal left) and 2 (parietal left) years survive after controlling for an injury severity index. Our finding that posterior DAR is a marker of PTCS and functional recovery post-injury, likely reflects functional de-afferentation of the posterior medial complex (PMC) in PTCS. Altered function of the PMC is proposed as a unifying physiological mechanism underlying both acute and chronic confusional states. We discuss the relationship of these findings to electrophysiological markers associated with disorders of consciousness.

Entities:  

Keywords:  EEG; cognitive outcomes; delirium; delta alpha ratio; post-traumatic confusional state

Mesh:

Year:  2017        PMID: 28462682     DOI: 10.1089/neu.2016.4911

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  6 in total

Review 1.  Organizing a Rational Approach to Treatments of Disorders of Consciousness Using the Anterior Forebrain Mesocircuit Model.

Authors:  Esteban A Fridman; Nicholas D Schiff
Journal:  J Clin Neurophysiol       Date:  2022-01-01       Impact factor: 2.590

Review 2.  Recovery from disorders of consciousness: mechanisms, prognosis and emerging therapies.

Authors:  Brian L Edlow; Jan Claassen; Nicholas D Schiff; David M Greer
Journal:  Nat Rev Neurol       Date:  2020-12-14       Impact factor: 42.937

3.  Hyperbaric oxygen therapy promotes consciousness, cognitive function, and prognosis recovery in patients following traumatic brain injury through various pathways.

Authors:  Yuwen Chen; Liang Wang; Wenjun You; Fei Huang; Yingzi Jiang; Li Sun; Siye Wang; Su Liu
Journal:  Front Neurol       Date:  2022-08-10       Impact factor: 4.086

4.  Is frontoparietal electroencephalogram activity related to the level of functional disability in patients emerging from a minimally conscious state? A preliminary study.

Authors:  Wanchun Wu; Chengwei Xu; Xiyan Huang; Qiuyi Xiao; Xiaochun Zheng; Haili Zhong; Qimei Liang; Qiuyou Xie
Journal:  Front Hum Neurosci       Date:  2022-09-29       Impact factor: 3.473

5.  Frail phenotype is associated with distinct quantitative electroencephalographic findings among end-stage renal disease patients: an observational study.

Authors:  Chia-Ter Chao; Hsin-Jung Lai; Hung-Bin Tsai; Shao-Yo Yang; Jenq-Wen Huang
Journal:  BMC Geriatr       Date:  2017-12-02       Impact factor: 3.921

Review 6.  Challenges of Delirium Management in Patients with Traumatic Brain Injury: From Pathophysiology to Clinical Practice.

Authors:  Shawniqua Williams Roberson; Mayur B Patel; Wojciech Dabrowski; E Wesley Ely; Cezary Pakulski; Katarzyna Kotfis
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.